Detail akcie Utd Therapeut online

Business Summary: United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Financial Summary: BRIEF: For the three months ended 31 March 2026, United Therapeutics Corp revenues decreased 2% to $781.5M. Net income decreased 15% to $274.9M. Revenues reflect Remodulin segment decrease of 8% to $126.6M, Unituxin segment decrease of 8% to $53.6M, Rest of World segment decrease of 17% to $37.3M, United States segment decrease of 1% to $744.2M. Net income also reflects Adcirca increase from $5.3M to $61.6M (expense).